Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept for CNV and FVP in PXE
NCT02537054Phase 2Completed
- Sponsor
- University Hospital Bonn
- Start
- Sep 2015
- Primary completion
- Jul 2018
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aflibercept in pseudoxanthoma elasticum (PXE) and choroidal neovascularization (CNV), sponsored by University Hospital Bonn. Primary endpoint: Change in distance best corrected visual acuity at day 360. Started Sep 2015; status: completed.
02
Drugs
aflibercept
03
Conditions
pseudoxanthoma elasticum (PXE)choroidal neovascularization (CNV)
Beyond the preview
Go deeper on NCT02537054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02537054.